RVU120 Rollover Study

Enrolling by invitation · Phase 2

Conditions studied: Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome

In brief

This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when continued under the same regimen as in the parent study. To be eligible for this rollover study, participants must be continuing to benefit from their treatment, show an acceptable safety profile, and not have access to commercially available comparator anticancer therapy. Once transitioned to this study, participants will continue with their next planned dose per the regimen of their parent study.

Key facts

Study ID

NCT06987058

Run by

Ryvu Therapeutics SA

People needed

14

Starts

2025-12-04

Expected to finish

2026-08-01

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant is enrolled in a RVU120 clinical study and receiving RVU120-based treatment given alone or in combination for at least 5 cycles.
• The participant is currently benefiting from, and expected to continue to benefit from, RVU120-based treatment according to the criteria set out in the parent study protocol and according to the judgment of the investigator and sponsor.
• The participant does not have access to commercially available comparator anticancer therapy.
• Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• The participant signed the rollover study ICF prior to any study-related procedure or study data collection.
• The participant agrees not to donate blood during study participation and until 28 weeks (\~6.5 months) after the last dose.
• The investigator considers the participant to be eligible for participation in the rollover study.

You may not qualify if…

• Presence of toxicity that cannot be adequately managed.
• Concurrent participation in any therapeutic clinical study other than the parent study.

Where it is running

• Uniwersyteckie Centrum Kliniczne — Gdansk, Poland
• Clinica Universidad de Navarra — Pamplona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.